Posts Tagged ‘Sepsis’
GenomeKey raise Innovate UK funding to drive life-saving next-gen sepsis diagnostic
Our member GenomeKey, has secured an Innovate UK Biomedical Catalyst research award of £950,000 towards faster diagnosis and treatment of sepsis, one of the world’s most deadly diseases. The funding will enable the Bristol-based research and development company to provide rapid bacterial species identification and antimicrobial profiling in the hospital, which will save lives, save money,…
Read MoreGenomeKey case study: Saving lives through early diagnosis of sepsis
To help our aspiring entrepreneurs and future SETsquared Bristol members, we showcase member and alumni case studies demonstrating the breadth of tech at SETsquared Bristol and what it takes to achieve success. We had a chat with GenomeKey CEO, Michael Roberts… GenomeKey Facts Start date: August 2019 Market sector: Medtech/diagnostics Location: Bristol Number of employees: 9 growing to 12 and beyond Amount…
Read MoreCARB-X is funding UK-biotech GenomeKey to develop a rapid diagnostic for sepsis, a leading cause of death in hospitals
(BOSTON) – CARB-X is awarding SETsquared Bristol member, GenomeKey (Genomics Labs Ltd.) in Bristol, UK, up to $9.5 million in grant funding to develop an innovative rapid diagnostic for sepsis. The new diagnostic would significantly reduce the time it takes to determine what bacteria are causing an infection and which antibiotics would be most effective…
Read MoreGenomeKey raises investment from Bristol Private Equity Club
A group of Bristol-based entrepreneurs has invested £192k into SETsquared Bristol member, GenomeKey, a research and development startup which is searching for faster diagnosis and treatment of sepsis. Sixteen members of Bristol Private Equity Club (BPEC) have backed GenomeKey, which is carrying out the pioneering research programme in Bristol. The investment will enable GenomeKey to leverage…
Read More